- Home
- OM vs RPID Comparison
OM vs RPID Comparison
Compare OM & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- RPID
- Stock Information
- Founded
- OM 2003
- RPID 2006
- Country
- OM United States
- RPID United States
- Employees
- OM N/A
- RPID N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- RPID Medical Specialities
- Sector
- OM Health Care
- RPID Health Care
- Exchange
- OM Nasdaq
- RPID Nasdaq
- Market Cap
- OM 44.0M
- RPID 37.3M
- IPO Year
- OM 2020
- RPID 2021
- Fundamental
- Price
- OM $1.14
- RPID $0.90
- Analyst Decision
- OM Buy
- RPID
- Analyst Count
- OM 4
- RPID 0
- Target Price
- OM $4.38
- RPID N/A
- AVG Volume (30 Days)
- OM 809.6K
- RPID 53.3K
- Earning Date
- OM 02-19-2025
- RPID 11-01-2024
- Dividend Yield
- OM N/A
- RPID N/A
- EPS Growth
- OM N/A
- RPID N/A
- EPS
- OM N/A
- RPID N/A
- Revenue
- OM $114,729,000.00
- RPID $26,170,000.00
- Revenue This Year
- OM N/A
- RPID $24.34
- Revenue Next Year
- OM $10.83
- RPID $19.49
- P/E Ratio
- OM N/A
- RPID N/A
- Revenue Growth
- OM N/A
- RPID 27.31
- 52 Week Low
- OM $0.44
- RPID $0.58
- 52 Week High
- OM $5.88
- RPID $1.34
- Technical
- Relative Strength Index (RSI)
- OM 59.79
- RPID 37.56
- Support Level
- OM $0.96
- RPID $0.97
- Resistance Level
- OM $1.23
- RPID $1.13
- Average True Range (ATR)
- OM 0.16
- RPID 0.07
- MACD
- OM -0.02
- RPID -0.01
- Stochastic Oscillator
- OM 46.53
- RPID 0.00
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company. It has developed a machine, Tablo, which reduces the cost and complexity of dialysis. Tablo provides Renal Replacement Therapy in Hospitals, Chronic Care in Dialysis Clinics and Home Dialysis.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.